Strategic partnerships AccessDx has actively pursued collaborations with healthcare providers and technology platforms (Spartanburg Ob-Gyn partnership; integration with PointClickCare). This suggests sales opportunities in expanding PGx testing enablement through partner networks and real-time care collaboration platforms.

Expansion footprint Licensed to run tests in all 50 states including New York and California, with recent event presence at major healthcare conferences (ASCP, NCDONA). There is potential to upsell to new markets and leverage conference exposure to drive trials and broader test adoption.

Precision medicine focus Portfolio combines pharmacogenomics and therapeutic drug monitoring within proprietary solutions to guide therapy decisions. This positions AccessDx to target top pharmacogenomics driven therapy areas and hospital systems seeking integrated, data-driven treatment customization.

Clinical data momentum Recent launches such as UTI PROx Panel and data intelligence from integrated diagnostics indicate a growing suite of actionable insights. There are opportunities to cross-sell additional panels and expand into infection-focused and tumor-diagnosis workflows with physicians.

Financial scale Revenue range of 25–50 million with a mid-sized employee base suggests agility to partner with mid-market health systems, ambulatory networks, and independent clinics for scalable testing programs, providing a path for volume-based contracts and bundled services.